Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth

M Aggarwal1, R Saxena2, E Sinclair1, Y Fu1, A Jacobs1, M Dyba1, X Wang3, I Cruz1, D Berry1, B Kallakury1, SC Mueller1, SD Agostino6, G Blandino4, ML Avantaggiati1 and F-L Chung*1

Mutations in the p53 tumor-suppressor gene are prevalent in human cancers. The majority of p53 mutations are missense, which can be classified into contact mutations (that directly disrupts the DNA-binding activity of p53) and structural mutations (that disrupts the conformation of p53). Both of the mutations can disable the normal wild-type (WT) p53 activities. Nevertheless, it has been amply documented that small molecules can rescue activity from mutant p53 by restoring WT tumor-suppressive functions. These compounds hold promise for cancer therapy and have now entered clinical trials. In this study, we show that cruciferous-vegetable-derived phenethyl isothiocyanate (PEITC) can reactivate p53 mutant under in vitro and in vivo conditions, revealing a new mechanism of action for a dietary-related compound. PEITC exhibits growth-inhibitory activity in cells expressing p53 mutants with preferential activity toward p53R175, one of the most frequent ‘hotspot’ mutations within the p53 sequence. Mechanistic studies revealed that PEITC induces apoptosis in a p53R175 mutant-dependent manner by restoring p53 WT conformation and transactivation functions. Accordingly, in PEITC-treated cells the reactivated p53R175 mutant induces apoptosis by activating canonical WT p53 targets, inducing a delay in S and G2/M phase, and by phosphorylating ATM/CHK2. Interestingly, the growth-inhibitory effects of PEITC depend on the redox state of the cell. Further, PEITC treatments render the p53R175 mutant sensitive to degradation by the proteasome and autophagy in a concentration-dependent manner. PEITC-induced reactivation of p53R175 and its subsequent sensitivity to the degradation pathways likely contribute to its anticancer activities. We further show that dietary supplementation of PEITC is able to reactivate WT activity in vivo as well, inhibiting tumor growth in xenograft mouse model. These findings provide the first example of mutant p53 reactivation by a dietary compound and have important implications for cancer prevention and therapy.

Cell Death and Differentiation (2016) 23, 1615–1627; doi:10.1038/cdd.2016.48; published online 3 June 2016

Effects of PEITC on proliferation of cells expressing p53 mutant. We examined the effects of PEITC in tumor cells harboring mutations at the hotspot codons 175, 248 and 273.
PEITC reduced proliferation of cells expressing different p53 mutants; however, maximal inhibition was observed in SK-BR-3, HOP92 and AU565 cells, which all express the p53R175 mutant (Figure 1a). In these cancer cells, PEITC exhibited IC₅₀s that were ∼2.5–5-fold lower than in cells with other hotspot mutations. No significant inhibition of proliferation was observed in cells harboring a p53 WT treated with PEITC.

PEITC inhibits proliferation and induces apoptosis in a p53R175-dependent manner. To determine whether the antiproliferative effects of PEITC are mediated through the reactivation of p53R175, we used cells transfected with control (NS) siRNA or p53 siRNA. The p53 protein was reduced by ≥90% after p53 siRNA transfection (Supplementary Figure S1a). In SK-BR-3 (Figure 1b), HOP92 (Supplementary Figure S1b) or AU565 (Supplementary Figure S1c) cells, the p53R175 knockdown resulted in markedly reduced sensitivity to growth inhibition by PEITC, whereas cells transfected with NS siRNA remained highly sensitive. No significant difference in proliferation was observed in A549 cells transfected with p53 siRNA or NS siRNA (Figure 1b). These results demonstrate that PEITC-induced growth inhibition is, at least partially, dependent on p53R175.

SK-BR-3 cells treated with 4 μM PEITC displayed an approximately threefold increase in the percentage of Annexin-V-stained cells (Figure 1c), compared with MDA-MB-231(p53R280), OVCAR3 (p53R248) (Supplementary Figure S1d) or A549 cells (Figure 1c). Importantly, there was no significant difference in apoptosis in p53R175 knockdown SK-BR-3 cells treated with PEITC or DMSO (Figure 1c), demonstrating that PEITC-induced apoptosis is p53R175 dependent.

To validate our results, we treated isogenic human H1299 (p53 null) cells transfected with plasmid pcDNA3, pcDNA3-p53R175, pcDNA3-p53R273 or pcDNA3-wtp53 with PEITC. The H1299-pcDNA3-p53R175 cells displayed maximum sensitivity to PEITC (Figures 1d and e). We used mouse embryonic fibroblast (MEF) cells lacking p53 gene (10)3, (10)3 cell-line-derived mutant p53 transfectants ((10)3/175 and (10)3/273) and WT p53 Balb/c 3T3 cells. Consistent with previous...
results, the p53R175 mutant was the most sensitive to PEITC (Supplementary Figures S1e and f). Collectively these results provide strong support to the notion that PEITC-induced growth inhibition preferentially occurs in cells harboring p53 R175.

**PEITC restores a ‘WT-like’ conformation and transactivation functions to p53R175.** As PEITC induced apoptosis in a p53 mutant-dependent manner, we reasoned that it may do so by restoring p53 WT function(s). Therefore, we examined its effect on the conformation of p53R175 with enzyme-linked immunosorbent assay (ELISA) using conformation-specific anti-p53 antibodies. Incubation of the recombinant glutathione-S-transferase (GST)–p53R175H with PEITC resulted in a ∼2.8-fold increase in the PAB1620 (WT-specific) fraction, whereas the PAB240 (mutant-specific) fraction was decreased by ∼2.6-fold (Figure 2a). An immunofluorescence assay on PEITC-treated SK-BR-3 cells showed an approximately twofold increase in the fluorescent intensity of PAB1620 antibody, whereas PAB240 antibody reactivity decreased (Figures 2b and c). Similar results were obtained with 10(3)/175 cells (Supplementary Figure S2a). Importantly, immunoprecipitation of p53R175 from SK-BR-3 cell lysates treated with PEITC showed a >95% decrease in the PAB240 immunoreactivity. These results demonstrate that PEITC induced a ‘WT-like’ conformation in p53R175.

DNA binding is critical for p53 functions. We examined whether PEITC enriches p53R175 in the chromatin fractions. The chromatin-bound fractions of SK-BR-3 cells treated with PEITC showed a dose-dependent increase in p53R175 (Figure 3a). Consistent with this, PEITC (4 μM) enhanced the expression of canonical p53 target genes, specifically p21, MDM2, PUMA, NOXA, BCL2 and BAX in SK-BR-3 cells (Figure 3b). No significant change was observed in A549, H1299 or p53 R175 knockdown SK-BR-3 cells treated with PEITC (4 μM), suggesting that the induction of p53 targets by PEITC was p53 R175 dependent (Figures 3b and c). Finally, we performed luciferase reporter assay. PEITC (4 μM)-treated SK-BR-3, AU565, HOP92 and (10)3/175 cells, transfected with plasmid encoding WT p53-binding element in the p21 promoter region, showed a ∼2–2.5-fold increase in luciferase activity (Figure 3d). PEITC (4 μM) induced p21 expression in the SK-BR-3 cells, whereas the DNA-damaging agent etoposide failed to do so (Figure 3e), suggesting that the induction was p53R175 dependent. These results demonstrate that PEITC restores a ‘WT-like’ conformation and transactivation function to p53R175.

**p53R175 protein undergoes degradation by the proteasome and autophagy.** PEITC (≥10 μM) selectively depletes p53 mutant protein, but not the WT p53, although the mechanisms of such depletion are still unknown.15 Previous studies have shown that compounds that reactivate mutant p53 also induce its partial depletion.16 To investigate
molecular mechanisms for p53R175 depletion, we evaluated p53 mutant levels with different doses and times of PEITC treatment. PEITC induced significant decrease of p53 R175 levels, at the concentration as low as 4 μM, (Supplementary Figures S3a–c). As PEITC restored p53R175 to the ‘WT-like’ form and p53 WT is regulated by the MDM2, the decreased stability of the restored p53 R175 might be due to the MDM2-dependent proteasome degradation. To test this, SK-BR-3 cells were co-treated with the proteasome inhibitor MG132 or Nutlin-3, a specific MDM2 inhibitor, and PEITC. MG132 or Nutlin-3 were unable to prevent the decrease in p53 R175 (Figure 4a). Studies have shown that inhibition of proteasome-dependent degradation of mutant p53 led to the accumulation of the ubiquitinated protein in the insoluble fraction. SK-BR-3 cells co-treated with PEITC (4 or 8 μM) and 20 μM MG132 showed a significant accumulation of the p53 in the insoluble fractions as well as in the whole-cell lysate (WCL) as compared with cells treated with PEITC or MG132 alone (Figure 4b). Similarly, SK-BR-3 cells co-treated with PEITC (4 or 8 μM) and 10 μM Nutlin-3 displayed an increase in p53 in the WCL (Figure 4c), whereas no difference in p53 accumulation was observed in A549 (Figure 4d). These results demonstrate that the reduced stability of the reactivated p53R175 is due to the proteasomal degradation.

SK-BR-3 cells treated with 8 μM PEITC alone showed p53 in the insoluble fraction (Figure 4b). The insoluble fractions were known to contain protein aggregates. To gain insights on aggregation of the p53 R175, we treated SK-BR-3 cells with a broad range (1–16 μM) of PEITC. Aggregation of p53 R175 occurs at higher concentrations (≥8 μM) (Figure 4e). As protein aggregates are cleared by autophagy, we investigated whether p53 R175 undergoes autophagy. SK-BR-3 cells co-treated with 8 μM PEITC and 50 μM chloroquine (CHQ), an inhibitor of autophagy, displayed an increase of p53 in the WCL compared with the cells treated with PEITC alone. No significant difference was observed for cells co-treated with 4 μM PEITC and 50 μM CHQ or PEITC alone, suggesting that autophagy was induced at higher concentrations of PEITC (Figure 5a). Autophagy protein 5 (ATG5) is required for autophagosome formation. ATG5-knockdown SK-BR-3 cells (Figure 5b) showed higher levels of p53R175 at 8 or 16 μM but not at 2 or 4 μM concentrations of PEITC compared with cells transfected with NS siRNA (Figure 5c). ATG5-knockdown SK-BR-3 cells were resistant to the anti-proliferative effects of PEITC, whereas NS siRNA-transfected
cells remained highly sensitive (Figures 5d and e), suggesting that in these cells autophagy negatively regulates cell growth. Together, these results demonstrate that PEITC depletes the p53 mutant from the cells by two different pathways: MDM2-dependent proteasome degradation for the reactivated p53 mutant and autophagy for the p53 R175 aggregates.

Effects of zinc and redox changes on PEITC-induced p53 R175 reactivation. Zinc ion is required for the proper folding of p53 WT protein. p53 R175 is incapable of binding to zinc.21 As PEITC restored the ’WT-like’ conformation to p53 R175, we assessed the effect of zinc on its antiproliferative activity. Co-treatment of SK-BR-3 cells with PEITC and zinc chloride (ZnCl2) in the optimal concentration range (10–20 μM) enhanced the potency of PEITC by ∼3.3-fold (Figure 6a) but not with ZnCl2 alone. Also, incubation of the GST-p53 R175 with PEITC (4 μM) and ZnCl2 (2.5 μM) resulted in significant increase in the PAB1620 fraction, whereas no significant change was detected in the PAB240 fractions (Figure 6b). These results demonstrate that PEITC induced ’WT-like’ conformation to p53 R175.

PEITC induces reactive oxygen species by disabling the GSH antioxidant system in cancer cells.14,22 Redox changes affect the conformation of p53 WT.23 Therefore, we evaluated the effect of PEITC on GSH levels in SK-BR-3 cells. SK-BR-3 cells treated with PEITC (4 or 8 μM) showed a decrease in the GSH levels as compared with the DMSO control (Figure 6c). Co-treatment of SK-BR-3 cells with PEITC and reducing agent (3 mM N-acetylcysteine (NAC) or 500 units PEG-catalase) alleviated the effects of PEITC on proliferation and apoptosis, whereas a catalase-specific inhibitor 3-amino-1,2,4-triazole (ATZ) enhanced it (Figures 6d–f). p53 R175-knockdown SK-BR-3 cells did not display significant differences in apoptosis upon treatment with PEITC alone or PEITC in combination with ATZ or NAC (Figure 6f). Importantly, co-treatment with PEITC and oxidizing or reducing agents had no effect on p53 R175H degradation and aggregation (Supplementary Figure S3d), suggesting that redox changes are important for reactivation of p53 R175 and inhibition of growth but not for restoring p53 R175 conformation.

Effects of PEITC on cell cycle and activation of ATM/CHK2. WT p53 has a role in DNA repair and in maintaining genomic stability. As PEITC restored transactivation functions to p53 R175 and exerted oxidative stress on SK-BR-3 cells, we evaluated its effect on DNA damage.24 SK-BR-3 cells treated with 4 μM PEITC displayed an ∼1.8-fold increase in γ-H2AX foci as compared with the DMSO control, indicating the accumulation of DNA double-strand breaks (DSBs), whereas no differences were detected in A549 cells (Figures 7a and b). Further, p53 R175-knockdown SK-BR-3 cells showed...
no difference in the number of γ-H2AX foci in cells treated with PEITC or DMSO (Supplementary Figures S4a and b), suggesting that accumulation of DSBs was p53 R175 dependent.

DSB activates the ataxia telangiectasia mutated (ATM) serine/threonine protein kinase, which then phosphorylates downstream signaling targets. The p53 R175H inactivates the ATM-dependent DNA-damage response and induces genetic instability, whereas p53-null cells are efficient in ATM activation. Autophosphorylation of ATM at S1981 was detected in H1299 cells treated with PEITC (Supplementary Figure S4c). Therefore, we examined whether the reactivation of p53 R175 to 'WT-like' p53 abolishes its ability to inhibit the activation of the ATM/Checkpoint kinase 2 (CHK2) pathways. SK-BR-3 cells treated with 4 μM PEITC showed pATM-S1981 and pCHK2/Thr68 compared with the DMSO control (Figure 7c), suggesting that the absence of inhibition of ATM/CHK2 by p53 R175H leads to the reactivation of the DNA-damage response. The absence of pATM-S1981 and pCHK2/Thr68 in A549 cells treated with PEITC was consistent with the γ-H2AX foci data (Figures 7a and b). Co-treatment of SK-BR-3 cells with PEITC and ATZ had no effect on pATM-S1981, whereas co-treatment with PEITC and NAC or PEG-Catalase completely abolished PEITC-induced ATM phosphorylation (Supplementary Figure S4d), suggesting that the reactivation of DNA-damage response by PEITC depends on redox state of the cells.

Next we examined whether reactivated p53 R175 mutant affects cell cycle progression. SK-BR-3 cells treated with PEITC (4 μM) displayed a significant increase in G2/M and S phases at 24 h (Figure 7d) and S-phase delay at 72 h (Supplementary Figure S5a), suggesting that PEITC inhibited cell proliferation by delaying cells not only in G2/M phase but also in the S phase. A549 cells treated with PEITC (4 μM) showed an increase in the G1 phase at 24 h, and no change at 72 h (Figure 7e; Supplementary Figure S5b). No significant delay in S and G2/M phases was observed in p53R175-knockdown SK-BR-3 cells treated with PEITC (Supplementary Figure S5c), suggesting that the delay in cell cycle progression was p53 R175 dependent.

We also examined the effects of Nutlin-3 and PEITC co-treatment on cell cycle progression and apoptosis. SK-BR-3 cells co-treated with 10 μM Nutlin-3 and 4 μM PEITC displayed remarkable increase in S-phase population (Figure 7d and Supplementary Figure S5a) and apoptosis (Figure 7i and Supplementary Figure S5d) at 24 and 72 h, respectively, compared with cells treated with PEITC or Nutlin-3 alone, indicating that Nutlin-3 exhibited a synergistic effect. Whereas, in A549 cells, Nutlin-3 treatment alone or in combination with PEITC resulted in a significant G1-phase delay at 24 h and G1 and G2/M-phase delays at 72 h (Figure 7e and Supplementary Figure S5b). Nutlin-3 alone induced apoptosis in A549 cells (Supplementary Figure S5d), demonstrating that the observed effects of Nutlin-3 were WT p53 specific.
Together, these results demonstrate that restoration of the transactivation functions to p53R175 by PEITC and reactivation of the DNA-damage response culminates in apoptosis.

**PEITC reactivates p53R175H in vivo and inhibits SK-BR-3 xenograft tumor growth.** The ability of PEITC to inhibit tumor growth in the SK-BR-3 xenograft mouse model was evaluated. A statistically significant inhibition of tumor growth (P < 0.05) was observed in mice on the PEITC diet (5 μmol/g AIN-93M) as compared with those on the control diet (Figures 8a and b and Supplementary Figure S6a). The decrease in tumor volumes in the control group after week 6 could be explained by the nonaggressive phenotype of the nu/nu mice as immune cells were detected in the hematoxylin and eosin (H&E)-stained sections (Supplementary Figure S6b). No difference in body weights was observed between the groups (Figure 8c). These results demonstrate that PEITC has antitumor activity in the SK-BR-3 xenograft model.

Histological examination revealed that tumor cells were remarkably depleted in the PEITC group (Figures 8a and d). A statistically significant reduction in Ki67- and p53-mutant-stained cells was detected in tumors from animals on the PEITC diet (Figure 8e). To assess whether PEITC induces p53R175H mutant reactivation in vivo, we examined p53 protein levels in the tumors. Because of the limited tumor tissues, especially from the PEITC-treated animals, the tumors were randomly divided for immunoblotting and quantitative real-time PCR (qRT-PCR) analysis. A significant reduction of p53 mutant protein levels was detected in animals on PEITC diet (Figure 8f). The variability in the reduced levels of p53 R175H in treated mice could be due to the inherent differences in this animal model. However, the p53 levels were consistently higher in the control group. Elevation in mRNA of p53-regulated genes and increase in p21 and Bax proteins were detected in animals fed PEITC diet (Figures 8g and h). These results provide evidence for the p53 mutant reactivation in vivo and the inhibition of SK-BR-3 xenograft tumor growth by PEITC.

**Discussion**

Reactivation of the transactivation functions to p53 mutants presents a promising strategy to target cancer cells selectively. The reactivation of p53 has been shown in mouse model. Synthetic small molecules that restore the p53 point mutant to
a transcriptionally competent form have been identified. However, studies exploring the potential of dietary-related molecules targeting p53 mutants are scarce. PEITC selectively depletes p53 mutant protein and not the WT. In this study, we revealed a novel mechanism for PEITC that it inhibits cell proliferation and induce apoptosis by reactivating p53 R175 to its WT function, resulting in the selective elimination of these cells. Similar effects were confirmed with human H1299 and MEF-derived p53 R175-transfectant cells.

Previous studies have shown that in the WT p53 cells PEITC induced apoptosis in a p53-dependent manner. However, in p53-deficient cells PEITC is shown to induce apoptosis by activating extracellular signal-regulated kinases (ERK1/2). Thus the reduced cell viability and increased apoptosis in both p53 R175H and p53 R175−/−, H1299 cells and MEF, by PEITC is consistent with the notion that pathway(s) independent of p53 mutational status also exists, such as depletion of tubulin in both WT and p53 mutant cells.

PEITC restored the transactivation functions to p53 R175H. Besides the antipoptotic regulator BCL2, PEITC induced the expression of several pro-apoptotic targets, including the members of BH3-only class. Importantly, BCL2 failed to suppress the cell death induced by PEITC. p53 regulates BCL2 family members by engaging multiple transactivation-dependent and -independent effectors. It will be interesting to study the crosstalk between the different genes in PEITC-treated cells that ultimately result in the cell death.

ZnCl₂ enhanced the antiproliferative activity of PEITC and also significantly increased the PAB1620 (WT-specific) fractions. Although, our results support that the reactivated p53 R175 could bind zinc, thereby allowing its proper folding, further experiments are required to understand the mechanism of zinc binding and the enhanced efficiency of PEITC. A metallochaperone function has been demonstrated for a small molecule that could restore WT-like conformation to the p53 R175H. Further studies are required to discern the role of PEITC as a source of zinc for the reactivated p53 R175. If PEITC indeed functions as a metallochaperone, it will be interesting to determine its effects on other zinc-binding mutants of p53, for example, C176F and C242F.

PEITC induced oxidative stress in SK-BR-3 cells, which may be exacerbated by increased ROS in p53 mutant cells (as p53-deficient cells are known for increased intracellular ROS). Although induction of ROS had no effect on the restoration of p53 R175H conformation, the elevated oxidative stress was responsible for the activation of the restored

Figure 7 PEITC induces γ-H2AX foci, activates ATM/CHK2, G2/M- and S-phase arrest and apoptosis. SK-BR-3 and A549 cells treated with PEITC or DMSO for 3 days were stained with anti-γ-H2AX antibody. (a) Merged images show cells stained with anti-γ-H2AX antibody (green) and DAPI (blue). All scale bars represents a size of 20 μm. (b) Percentage of cells with γ-H2AX foci (≤10 or > 10, as indicated). (c) SK-BR-3 and A549 cells were treated with PEITC or DMSO for 4 h. Western blotting was performed using anti-pATM S1981 and anti-pCHK2 Thr68 antibodies. Blots were stripped and reprobed with anti-ATM and anti-CHK2 antibodies. (d) SK-BR-3 or (e) A549 cells were treated with PEITC, 10 μM Nutlin-3 or both for 24 h and analyzed by flow cytometry. (f) SK-BR-3 and A549 cells were treated with 4μM PEITC, 10 μM Nutlin-3 or both for 24 h. Apoptosis was measured by Annexin-V staining using a BD LSRFORTESSA instrument.
p53\textsuperscript{R175} and induction of apoptosis. In support of this, ATZ enhances the antiproliferative ability of PEITC, whereas PEG-Catalase or NAC inhibits it. As a proof-of-principle, we demonstrated that p53 \textsuperscript{R175H} can be reactivated \textit{in vivo} by dietary PEITC. We found 1.13 ± 0.15 μM ITC in the blood samples of the mice fed PEITC. Pharmacokinetic studies in humans have shown that after consuming ∼50 g of uncooked watercress (approximately equivalent to 40 mg PEITC) a peak concentration of 1 μM PEITC can be reached in the plasma.\textsuperscript{34,35} Reactivation of mutant p53 has been shown previously in xenograft models under 'chemotherapeutic settings' where tumors are formed before the systemic administration of the drugs.\textsuperscript{29,30} In this study, the inhibitory effect of PEITC was demonstrated under conditions that mimic cancer 'chemopreventive settings'. In this bioassay, the animals were fed diets containing PEITC before the injection of the p53 mutant cells and formation of tumors, and mutant cells were then injected to mimic the presence of 'cancerous' or 'initiated' cells. Mice fed PEITC displayed a statistically significant decrease in tumor volumes, inhibition of proliferation and depletion of the p53\textsuperscript{R175H} \textit{in vivo}. The elevated mRNA of p53 target genes from mice fed PEITC provides evidence for p53 \textsuperscript{R175H} reactivation.

Significant efforts have been made to identify small molecules as therapeutics from chemical libraries aimed at reactivating p53 mutants. However, target-based prevention studies by dietary compounds are scarce. Our study elucidates a novel mechanism for PEITC, by preferential targeting of p53 \textsuperscript{R175}. Given that the R175 mutation is the third most common missense mutation among p53 mutants in human cancers, with an estimated 5.1% frequency of occurrence,\textsuperscript{36} PEITC may be developed as a lead compound for tumors with p53 \textsuperscript{R175}. Mutations in the p53 gene may occur at different phases during tumorigenesis, such as in the late stages of pancreatic neoplasia,\textsuperscript{37} hepatocellular carcinoma,\textsuperscript{38} prostate cancer\textsuperscript{39} and so on but in the early phases of ductal carcinoma \textit{in situ} (DCIS), a precancerous lesion of breast\textsuperscript{40}

**Figure 8** PEITC induces p53\textsuperscript{R175H} mutant reactivation \textit{in vivo} and inhibits xenograft tumor growth. (a) Representative images of mouse mammary fat pads (upper panel), and H&E staining (lower panel). All scale bars represents a size of 200 μm. (b) Tumors were measured with Vernier calipers, and tumor volumes were calculated. Formula $L \times W^2 \times 0.523$ (**$P \leq 0.009$ and **$P \leq 0.03; n = 7$). (c) Animal weights (g) were measured weekly. (d) Distribution of the animals based on the average number of tumor cells per tissue section in the control and PEITC groups (**$P \leq 0.00026; n = 7$). (e) Representative images of xenograft tumor tissue stained for Ki67 (**$P \leq 0.007$) and p53 (**$P \leq 0.030$) (upper panel) and quantitation of positive cells (lower panel) ($n = 7$). Results are expressed as ± S.D. All scale bars represents a size of 200 μm. (f) Western blotting analysis of p53 expression levels in the xenograft tumors from the PEITC and control animal groups. Blot is representative of the 12 tumor tissue lysates analyzed from each group. (g) qRT-PCR ($n = 4$) of p53-regulated genes in the PEITC and control animal groups. (h) Western blotting of p21 and Bax expression in SK-BR-3 xenograft tumors \textit{in vivo}.
and liver cancer.\footnote{1} The occurrence of p53 mutations before the development of invasive breast cancer, particularly in DCIS, suggests the potential of PEITC in the prevention of breast cancer. Besides p53R175, PEITC inhibited the proliferation and induced apoptosis of cell lines with other hotspot mutants, including DNA contact mutants. More studies are needed to understand the mechanisms of growth inhibition of these mutants by PEITC. Nevertheless, the finding that a dietary-related compound restores the 'WT-like' conformation and functions to the p53R175 opens up an opportunity for implementing a practical and effective target-based strategy for cancer prevention and treatment.

**Materials and Methods**

**Cell lines.** HOP92, OVCA3 and SW620 were ordered from NCI DTP. CDC7 Tumor Repository, Fredrick, MD, USA. H1299, HT29, A549, MDA-MB-231, AU565, SK-BR-3 and MCF7 were obtained from Tissue Culture Source Resource, Madison, WI, USA. Cultures were maintained in RPMI 1640 containing 10% FBS. Colon cancer cells Caco2 were purchased from ATCC (Manassas, VA, USA) were cultured in Eagle’s minimal essential medium with 10% FBS. 3T3 Balbc fibroblasts (p53\textsuperscript{-/-}) were purchased in Dulbecco’s modified Eagle’s medium with 10% FBS. (10^3) (p53\textsuperscript{-/-}) MEFs and (10^3) 3–derived MEFs with p53 mutations ((10^3)175 and (10^3)273) were cultured in Dulbecco’s modified Eagle’s medium with 10% FBS and 400 μg/ml G418. The MEF (10^3)175 and its derivative cells with human p53 mutations at residues R175 and R273 were previously derived and were a gift from Dr. Darren R Carpizo.

**Cell proliferation assays.** The effect of PEITC on SK-BR-3 cell proliferation was determined by using the WST-1 assay (Roche, Indianapolis, IN, USA) as described previously\textsuperscript{3} and was a gift from Dr. Darren R Carpizo. (10^3)3 and its derivative cells with human p53 mutations at residues R175 and R273 were previously derived and were a gift from Dr. Darren R Carpizo.

**Materials and Methods**

**Cell lines.** HOP92, OVCA3 and SW620 were ordered from NCI DTP. CDC7 Tumor Repository, Fredrick, MD, USA. H1299, HT29, A549, MDA-MB-231, AU565, SK-BR-3 and MCF7 were obtained from Tissue Culture Source Resource, Madison, WI, USA. Cultures were maintained in RPMI 1640 containing 10% FBS. Colon cancer cells Caco2 were purchased from ATCC (Manassas, VA, USA) were cultured in Eagle’s minimal essential medium with 10% FBS. 3T3 Balbc fibroblasts (p53\textsuperscript{-/-}) were purchased in Dulbecco’s modified Eagle’s medium with 10% FBS. (10^3) (p53\textsuperscript{-/-}) MEFs and (10^3) 3–derived MEFs with p53 mutations ((10^3)175 and (10^3)273) were cultured in Dulbecco’s modified Eagle’s medium with 10% FBS and 400 μg/ml G418. The MEF (10^3)175 and its derivative cells with human p53 mutations at residues R175 and R273 were previously derived and were a gift from Dr. Darren R Carpizo.

**Cell proliferation assays.** The effect of PEITC on SK-BR-3 cell proliferation was determined by using the WST-1 assay (Roche, Indianapolis, IN, USA) as described previously\textsuperscript{3} and was a gift from Dr. Darren R Carpizo. (10^3)3 and its derivative cells with human p53 mutations at residues R175 and R273 were previously derived and were a gift from Dr. Darren R Carpizo.

**Materials and Methods**

**Cell lines.** HOP92, OVCA3 and SW620 were ordered from NCI DTP. CDC7 Tumor Repository, Fredrick, MD, USA. H1299, HT29, A549, MDA-MB-231, AU565, SK-BR-3 and MCF7 were obtained from Tissue Culture Source Resource, Madison, WI, USA. Cultures were maintained in RPMI 1640 containing 10% FBS. Colon cancer cells Caco2 were purchased from ATCC (Manassas, VA, USA) were cultured in Eagle’s minimal essential medium with 10% FBS. 3T3 Balbc fibroblasts (p53\textsuperscript{-/-}) were purchased in Dulbecco’s modified Eagle’s medium with 10% FBS. (10^3) (p53\textsuperscript{-/-}) MEFs and (10^3) 3–derived MEFs with p53 mutations ((10^3)175 and (10^3)273) were cultured in Dulbecco’s modified Eagle’s medium with 10% FBS and 400 μg/ml G418. The MEF (10^3)175 and its derivative cells with human p53 mutations at residues R175 and R273 were previously derived and were a gift from Dr. Darren R Carpizo.

**Cell proliferation assays.** The effect of PEITC on SK-BR-3 cell proliferation was determined by using the WST-1 assay (Roche, Indianapolis, IN, USA) as described previously\textsuperscript{3} and was a gift from Dr. Darren R Carpizo. (10^3)3 and its derivative cells with human p53 mutations at residues R175 and R273 were previously derived and were a gift from Dr. Darren R Carpizo.

**Cell proliferation assays.** The effect of PEITC on SK-BR-3 cell proliferation was determined by using the WST-1 assay (Roche, Indianapolis, IN, USA) as described previously\textsuperscript{3} and was a gift from Dr. Darren R Carpizo. (10^3)3 and its derivative cells with human p53 mutations at residues R175 and R273 were previously derived and were a gift from Dr. Darren R Carpizo.
cytoplasmic histone-associated DNA fragments indicative of ongoing apoptosis were measured quantitatively using the cell death detection ELISA PLUS photometric enzyme assay (Roche).

**Immunofluorescent staining.** SK-BR-3, A549, H1299 and (10)3/175 cells were treated with PEITC (4 or 6 μM) or 1% DMSO as a control for 4 h in slide chambers with four wells (ThermoFisher Scientific). Cells then were washed twice with 1 × PBS and fixed with formaldehyde (3.7%) at RT for 15 min. Fixed cells were washed four times with 1 × PBS and treated with 0.5% Triton X-100 (Sigma) at RT for 5 min. Cells were washed four times with 1 × PBS containing 0.5% Tween-20 and blocked with 10% goat serum (Sigma) overnight at 4 °C. Cells were washed four times with 0.1% Tween-20 and incubated with mouse PAB240 (1:300, Calbiochem, San Diego, CA, USA) or mouse PAB1620 (1:300, Calbiochem) that recognizes specifically the mutant or p53 WT, respectively, overnight at 4 °C. After four washes with 0.1% Tween-20, cells were incubated with Alexa Fluor 488-conjugated goat anti-mouse IgG (1:400, Invitrogen) for RT at 2 h. Cells were washed four times with 0.1% Tween-20 and coated with Prolong Gold Anti-Fade reagent (Invitrogen) containing DAPI. Coverslips were placed on the chamber slides, and cells were cured at RT in the dark for 24 h. Immunofluorescence analyses were performed with a Zeiss LSM 510 META NLO inverted Axiovert 200 M laser scan microscope (Thornwood, NY, USA) with a Plan-Apochromat 63 × 1.4 numerical aperture oil immersion objective lens. Images were captured using the Photomultiplier Tube detectors and analyzed using the Image J software (NIH, available at http://rsb.info.nih.gov/ij/). Fluorescent staining intensity was quantified using the Metamorph software (Sunnyvale, CA, USA).

To determine the effect of PEITC on γ-H2AX foci formation in SK-BR-3 cells, transfected with p53 siRNA or NS siRNA or A549 cell lines, cells were treated with 4 μM PEITC or 1% DMSO as a control at 37 °C for 3 days. Cells were fixed with formaldehyde and processed for immunostaining to detect γ-H2AX foci as described above, except that mouse anti-γ-H2AX monoclonal antibody (1:300, Upstate, EMD Millipore, Billerica, MA, USA) was used as a primary antibody.

**Co-immunoprecipitation.** SK-BR-3, A549 and HOP92 cells were treated with the indicated concentration of PEITC or 1% DMSO as a control for 6 h. For preparation of cell lysates, cells were harvested and washed once with 1 × PBS, cell pellets were suspended in lysis buffer (20 mM Tris-Cl (pH 8.0), 137 mM sodium chloride, 10% glycerol, 1% NP-40, 2 mM EDTA) and Protease inhibitors (Roche, Indianapolis, IN, USA) and the cells were incubated on ice for 30 min. The cell suspension was centrifuged at 18 500 × g for 10 min at 4 °C, and the supernatant was collected. The supernatants were diluted in lysis buffer, and 200 μg of the lysate was gently tumbled at 4 °C for 1 h with protein G-agarose beads (Roche). The lysates obtained after preclaring were then gently tumbled at 4 °C for 2 h with mouse PAB240 antibody (2 μg, Calbiochem). Protein G-agarose beads were then added to the suspensions and incubation was performed for 2 h at 4 °C. The beads were washed four times with lysis buffer supplemented with protease inhibitors, and the immunoprecipitates were eluted by boiling in Laemmli buffer and resolved on 4–12% SDS-PAGE. Immunoprecipitated p53 was detected by western blotting using FL393 (Santa Cruz Biotechnology) as a primary antibody. For the secondary antibody, peroxidase-labeled anti-mouse IgG (1:2000, GE Healthcare, Pittsburgh, PA, USA) was used. The blot was developed using the ECL Prime Western Blot Detection Kit according to the manufacturer's protocol (Ammeshan, GE Healthcare). As a control, the blot was stripped and then reprobed with anti-p53 (DO-1) antibody (1:1000, Santa Cruz Biotechnology) or anti-GAPDH antibody (1:2000, Novus Biologicals, Littleton, CO, USA). The density of the p53 bands in the PEITC treated samples relative to that of DMSO control was determined using the GeneTools software (Cambridge, England, UK).

**Lysate preparation and western blotting analysis.** Different lysates buffers were used to prepare soluble, insoluble and WCL fractions. For lysate (soluble fraction) preparation, cells were harvested and washed twice with 1 × PBS. RIPA buffer (10 mM sodium phosphate (pH 7.2), 300 mM NaCl, 0.1% SDS, 1% Nonidet P-40, 1% deoxycholate, 2 mM EDTA) was added to the cells, and the cells were incubated on ice for 30 min. Then the cell suspension was centrifuged at 18 500 × g for 10 min at 4 °C and the supernatant was collected, unless mentioned otherwise. The remaining pellet was defined as insoluble fraction. Insoluble fractions were dissolved in 2% SDS lysis buffer (65 mM Tris-Cl (pH 8.0), 150 mM NaCl, 2% SDS, 50 mM DTT). For WCL fractions, cells were harvested and the pellets were dissolved in 2% SDS lysis buffer as described previously. The fractions were collected by centrifuging the lysate at 18 500 × g for 10 min at 4 °C. Then 30–50 μg of the lysates were loaded on 4–12% SDS/PAGE. Protein was transferred onto a PVDF membrane, and the blots were developed using the ECL Prime Western Blot Detection Kit according to the manufacturer’s protocol (Ameshan). The antibodies for p21, Bax, ATM, pATM S1981, CH2K, pCHK2 Thr68 and p53 (DO-1) were purchased from Santa Cruz Biotechnology and GAPDH antibody was from Novus Biologicals. The antibody for ATGS (1 : 1000, Cell Signaling, EMD Millipore, Danvers, MA, USA) was a gift from Dr. Shivendra V Singh.

**Chromatin fractionation.** SK-BR-3 cells were treated with the indicated concentrations of PEITC or DMSO as a control for 4 h. Cells were trypsinized and harvested by centrifugation at 500 × g for 5 min. Cell pellets were washed once with ice-cold PBS and transferred to 1.5-ml microcentrifuge tubes followed by centrifugation at 500 × g for 2 min. Pellets were stored at −80 °C prior to chromatin fractionation following the manufacturer's instruction (Subcellular Protein Fractionation Kit, Thermo Scientific) to generate nuclear soluble and chromatin-bound protein fractions. Ten micrograms of protein from the soluble nuclear extract and the chromatin-bound nuclear extract for the samples from DMSO- or PEITC-treated cells were resolved on 4–12% SDS-PAGE and transferred to PVDF membranes. Blots were probed with p53 (DO-1) antibody (1 : 1000, Santa Cruz Biotechnology). Histone H3 and TopIIß, which served as markers for the chromatin and soluble nuclear fractions, respectively, were detected with rabbit anti-Histone H3 polyclonal (Thermo Scientific) and mouse anti-TopIIß monoclonal (Santa Cruz Biotechnology) antibodies.

**RNA extraction and qRT-PCR.** SK-BR-3, SK-BR-3 transfected with p53 siRNA or NS siRNA, H1299 and A549 cells were treated with 4 μM PEITC or DMSO as a control for 4 h. RNA was extracted from the cells using a Qiagen RNeasy Kit (Qiagen, Valencia, CA, USA), cDNA was synthesized by using High Capacity RNA to cDNA Kit (Applied Biosystems, Invitrogen, ThermoFisher Scientific) and the gene expression level was measured by qRT-PCR using TaqMan gene expression assays (Applied Biosystems, Invitrogen). The gene expression level is normalized with GAPDH, and the average is presented with S.D. from triplicates of repeated experiments. RNA was extracted from the SK-BR-3 xenograft tissues by using Qiagen RNeasy Kit and was processed further for qRT-PCR as described for the SK-BR-3 cells. The gene expression levels were normalized with GAPDH. Fold changes in the gene expression levels were calculated for each tumor from the treated group relative to the tumors from the control group and the average is presented with S.D.

**Measurement of glutathione level.** The levels of reduced glutathione (GSH) and oxidized glutathione (GSSG) were measured using the GSH/GSSG-Glo Glutathione assay Kit (Promega). Briefly, SK-BR-3 cells were treated with PEITC or DMSO as a control for 4 h. Cells were then processed for the glutathione assay as per the manufacturer's instructions (Promega).

**Luciferase reporter assay.** WWP-Luc (p21/WAF1 promoter) plasmid encoding p53 WT-binding element in the p21 promoter region was a gift from Bert Vogelstein (Addgene plasmid no. 16451, Cambridge, MA, USA).43 It was transfected into SK-BR-3, A549, H1299 and MEF ((10)3/175 and (10)273) cells, followed by treatment with PEITC (4 or 6 μM) for 24 h. The cell lysate was made and the luciferase reporter assay was performed in accordance with the manufacturer's instructions (Luciferase assay, Promega).

**Cell cycle analysis.** SK-BR-3, SK-BR-3 transfected with p53 siRNA or NS siRNA and A549 cells were treated with PEITC, Nutlin-3 or both or DMSO as a control for 24 or 72 h. Cells then were prepared for flow cytometric analysis. Briefly, cells were washed with PBS free of Ca2+ and Mg2+; trypsinized for 5 min and harvested by centrifugation at 150 × g for 3 min at 4 °C. Cells were washed once with PBS and the pellets resuspended in 1 ml of 70% ethanol and stored at −20 °C overnight. Cells were harvested by centrifugation at 420 × g for 10 min. The cell pellets were washed once with 1 ml cold PBS and resuspended in 1 ml freshly prepared PI staining solution (PBS with 0.1% Triton X-100, 0.05 μg/ml propidium iodide, 0.1 mg/ml RNase (Sigma)). The cell suspension was incubated at RT for 30 min in the dark followed by incubation for 30 min at 4 °C. The samples were run on a Becton Dickinson FACs sorter (BD Biosciences, San Jose, CA, USA) and the data were analyzed using Mod Fit program (Verity Software House, Topsham, ME, USA).

**Detection of ATM and CHK2 phosphorylation upon PEITC treatment.** Cells were treated with either DMSO, ATZ, NAC, PEG-Catalase or PEITC alone or PEITC in combination with ATZ or NAC or PEG-Catalase for 4 h. Cells then were harvested by centrifugation at 1600 × g for 10 min at 4 °C, washed once with PBS and resuspended in RIPA buffer (10 mM sodium phosphate (pH 7.2),
300 mM NaCl, 0.1% SDS, 1% Nonidet P-40, 1% deoxycholate and 2 mM EDTA containing a protease and phosphatase inhibitor mixture and were incubated on ice for 30 min and centrifuged at 18,500 × g for 10 min at 4 °C. The supernatant was collected, and 200 μg of the lysate was loaded on 4–12% SDS/PAGE. Following electrophoresis, protein was transferred onto a PVDF membrane, and blot was probed with anti-pATM Ser1981 antibody (1:500) (Santa Cruz Biotechnology) or anti-pCHK2 Thr68 antibody (1:500) (Santa Cruz Biotechnology). For the secondary antibody, peroxidase-labeled anti-mouse IgG (1:1000, GE Healthcare) was used. The blot was developed using the ECL Prime Western Blot Detection Kit following the manufacturer’s protocol (Amersham). As a control, the blot was stripped and then reprobed with anti-ATM anti-body (1:500, Santa Cruz biotechnology) or CHK2 antibody (1:500, Santa Cruz biotechnology).

Mouse SK-BR-3 xenograft model. Twenty female athymic nu/nu Balb/c mice (CAnN.Cg-Foxn1nu/Crl, 4–6-week old) were purchased from Charles River Laboratories (Wilmington, MA, USA). All the animals were killed, and the tumors were removed and were weighed. The samples from the xenograft model. Twenty female athymic nu/nu Balb/c mice were used. The blot was developed using the ECL Prime Western Blot Detection Kit following the manufacturer’s protocol (Amersham). As a control, the blot was stripped and then reprobed with anti-ATM antibody (1:500, Santa Cruz biotechnology) or CHK2 antibody (1:500, Santa Cruz biotechnology).

Dietary isothiocyanate reactivates p53 mutant

M Amgarwal et al

1. Liu G, McConnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK et al. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA 2000; 97: 4174–4179.
2. Muller RH, Caswell PT, Doyle B, Iwanczyk MP, Tan EH, Karim S et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139: 1327–1341.
3. Dittmer D, Pati S, Zambetti G, Chu S, Teresiuk AK, Moore M et al. Gain of function mutations in p53. Nat Genet 1993; 4: 42–48.
4. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998; 90: 606–611.
5. WHO. IARC Handbook on Cancer Prevention. Cruciferous Vegetables, Isothiocyanates and Indoles, vol. 9. IARC Press: Lyon, France, 2004.
6. Talalay P, Fahey JW. Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism. J Nutr 2001; 131: 3027S–3033S.
7. Rose P, Whittem M, Huang SH, Hallwell B, Ong CN, beta-Phenylethyl Isothiocyanate-mediated apoptosis in hepatoma HepG2 cells. Cell Mol Life Sci 2003; 60: 1489–1503.
8. Huang C, Ma WY, Li J, Hecht SS, Dong Z. Essential role of p53 in phenethyl isothiocyanate-induced apoptosis. Cancer Res 1998; 58: 4106–4108.
9. Conaway CC, Yang YM, Chung FL. Isothiocyanates as cancer chemopreventive agents: their biochemical activities and metabolism in rodents and humans. Curr Drug Metab 2002; 3: 233–255.
10. Kessler TW, Egner PA, Agemyan AS, Visvanathan K, Groopman JD, Chen JG et al. Keap1-nrf2 signaling: a target for cancer prevention by sulforaphane. Top Cur Chem 2013; 1502: 165–177.
11. Kong AL, Owuor E, Yu R, Hebbbar V, Chen C, Hu R et al. Induction of xenobiotic enzymes by the MAP kinase pathway and the antioxidant or electrophile response element (ARE/EpRE). Drug Metab Rev 2001; 33: 255–271.
12. Xiao D, Singh SV. Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res 2002; 62: 3615–3619.

13. Xiao D, Lew KL, Zeng Y, Xiao H, Marynowski SW, Dhir R et al. Phenethyl isothiocyanate-induced apoptosis in PC-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential. Carcinogenesis 2006; 27: 2223–2234.

14. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H et al. Selective killing of oncogeneally transformed cells through a ROS-mediated mechanism by beta-phenethyl isothiocyanate. Cancer Cell 2006; 10: 241–252.

15. Wang X, Di Pasqua AJ, Govind S, McCracken E, Hong C, Mi L et al. Selective depletion of mutant p53 by cancer chemopreventive isothiocyanates and their structure-activity relationships. J Med Chem 2011; 54: 809–816.

16. Garufi A, Pucci D, D’Orazi V, Cirone M, Bossi G, Avantaggiati ML et al. Degradation of mutant p53H175 protein by Zn(II) through autophagy. Cell Death Dis 2014; 5: e1271.

17. Ryan KM, Phillips AC, Vouwen KH. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 2001; 13: 332–337.

18. Whitesell L, Suphun P, An WG, Schulte T, Blagosklonny MV, Neckers L. Gelaldamycin-in-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene 1997; 14: 2809–2816.

19. Choudhury S, Kolukula VK, Preet A, Albanese C, Avantaggiati ML. Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy? Cell Cycle 2013; 12: 1022–1029.

20. Bommarredy A, Ham R, Xiao D, Powolny AA, Fisher AL, Jiang Y et al. Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells. Cancer Res 2009; 69: 3704–3712.

21. Joerger AC, Fersht AR. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 2007; 26: 2226–2242.

22. Xiao D, Powolny AA, Mours MB, Kelley EE, Bommarredy A, Kim SH et al. Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated degradation of human p53. Cancer Res 2007; 67: 4366–4369.

23. Hainaut P, Milner J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res 1993; 53: 4469–4473.

24. Woodbine L, Bruntun H, Goodarzi AA, Shibata A, Jeggo PA. Endogenously induced DNA double strand breaks arise in heterochromatin DNA regions and require ataxia telangiectasia mutated and Artemis for their repair. Nucleic Acids Res 2011; 39: 6988–6997.

25. Liu DP, Song H, Xu Y. A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 2010; 29: 949–956.

26. Ekild KI, Morse MA, Chung FL. Distribution and metabolism of the natural anticarcinogen phenethyl isothiocyanate in A/J mice. Carcinogenesis 1990; 11: 2033–2036.

27. Iorns E, Hnatyszyn HJ, Saeo P, Clarke J, Ward T, Lippman M. The role of SA TB1 in breast cancer pathogenesis. J Natl Cancer Inst 2010; 102: 1284–1296.

28. Ventura A, Kirsch DG, McLachlin ME, Tuveson DA, Grimm J, Lintaut L et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 448: 661–665.

29. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8: 282–288.

30. Yu X, Vazquez A, Levine AJ, Carpio DR. Allele-specific p53 mutant reactivation. Cancer Cell 2012; 21: 614–625.

31. Mi L, Gan N, Cheema A, Dakshinamurthy S, Wang X, Yang DC et al. Cancer preventive isothiocyanates induce selective degradation of cellular alpha- and beta-tubulins by proteasomes. J Biol Chem 2009; 284: 17039–17051.

32. Hemann MT, Lowe SW. The p53-Bcl-2 connection. Cell Death Differ 2006; 13: 1256–1259.

33. Sabtina AA, Budanov AV, Ilyinakaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antion-fiant function of the p53 tumor suppressor. Nat Med 2005; 11: 1306–1313.

34. Liesen J, Conaway CC, Hochster M, Mendoza S, Hecht SS, Crowell J et al. High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate. Anal Biochem 2001; 291: 279–289.

35. Getahun SM, Chung FL. Conversion of glucosinolates to isothiocyanates in humans after ingestion of cooked watercress. Cancer Epidemiol Biomarkers Prev 1999; 8: 447–451.

36. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev 2012; 26: 1268–1286.

37. Huban RH, Goggin M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6: 2969–2972.

38. Oda T, Tsuda H, Scarpa A, Saikamoto M, Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 1992; 52: 6358–6364.

39. Kubota Y, Shui T, Uemura H, Fujinami K, Miyamoto H, Torigoe S et al. Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 1995; 26: 16–24.

40. DONE SJ, Eskandarian S, Bull S, Redston M, Andrusila IL, p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. J Natl Cancer Inst 2003; 95: 700–704.

41. Iakovou P, Timchenko L, Timchenko NA. Intracellular signaling and hepatocellular carcinoma. Semin Cancer Biol 2011; 21: 28–34.

42. Aggarwal M, Sommers JA, Shoemaker RH, Bross RM Jr. Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress. Proc Natl Acad Sci USA 2011; 108: 15358–15363.

43. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–825.

44. Conaway CC, Wang CX, Pittman B, Yang YM, Schwartz JE, Tian D et al. Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice. Cancer Res 2005; 65: 8548–8557.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, you may need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/